Tophus measurement as an outcome measure for clinical trials of chronic gout: Progress and research priorities

Journal of Rheumatology

Volumn 38, Issue 7, 2011, Pages 1458-1461

  Dalbeth, Nicola ^a   McQueen, Fiona M ^a   Singh, Jasvinder A ^b   MacDonald, Patricia A ^c   Edwards, N Lawrence ^d   Schumacher Jr , H Ralph ^e   Simon, Lee S ^f   Stamp, Lisa K ^g   Neogi, Tuhina ^h   Gaffo, Angelo L ^b   Khanna, Puja P ⁱ   Becker, Michael A ^j   Taylor, William J ^k  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c TAKEDA PHARMACEUTICALS   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f SDG LLC   (United States)

^g UNIVERSITY OF OTAGO   (New Zealand)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k UNIVERSITY OF OTAGO   (New Zealand)

more..

Author keywords

Gout; Outcome measure; Tophus

Indexed keywords

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTHROPATHY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC TEST; DISEASE COURSE; ECHOGRAPHY; FILTER; GOUT; HUMAN; MEASUREMENT; MEDICAL PHOTOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RELIABILITY; RESEARCH PRIORITY; SYSTEMATIC REVIEW; TOPHUS; VERNIER CALIPER; VOLUMETRY; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL RESEARCH; CRYSTALLOID; DIGITAL IMAGING; FEASIBILITY STUDY; PHOTOGRAPHY; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; SUBCUTANEOUS TISSUE; URIC ACID STONE;

CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; GOUT; GOUT SUPPRESSANTS; HUMANS; JOINTS; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

FEBUXOSTAT;

EID: 79959968230     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110272     Document Type: Conference Paper

References (17)

1. Dalbeth N, Pool B, Gamble GD, Smith T, Callon KE, McQueen FM, et al. Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum 2010;62:1549-56.
2. Dalbeth N, Clark B, Gregory K, Gamble G, Sheehan T, Doyle A, et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann Rheum Dis 2009;68:1290-5.
3. Dalbeth N, Collis J, Gregory K, Clark B, Robinson E, McQueen FM. Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology 2007;46:1804-7. (Pubitemid 350168295)
4. Taylor WJ, Schumacher HR Jr, Baraf HS, Chapman P, Stamp L, Doherty M, et al. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Ann Rheum Dis 2008;67:888-91. (Pubitemid 351829395)
5. Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, et al. Outcome domains for studies of acute and chronic gout. J Rheumatol 2009;36:2342-5.
6. Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, et al. Progress in measurement instruments for acute and chronic gout studies. J Rheumatol 2009;36:2346-55.
7. Dalbeth N, Schauer C, MacDonald P, Perez-Ruiz F, Schumacher HR, Hamburger S, et al. Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide. Ann Rheum Dis 2011;70:597-604.
8. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61. (Pubitemid 41781828)
9. Becker MA, Schumacher HR Jr, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009;36:1273-82.
10. Schumacher HR Jr, Becker MA, Wortmann RL, MacDonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8.
11. Schumacher HR Jr, Becker MA, Palo WA, Streit J, MacDonald PA, Joseph-Ridge N. Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol 2005;32:2368-72. (Pubitemid 41780649)
12. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60. (Pubitemid 34856121)
13. Maroli AN, Waltrip R, Alton M, Herbert S, Baraf B, Huang B, et al. First application of computer-assisted analysis of digital photographs for assessing tophus response: phase 3 studies of pegloticase in treatment failure gout [abstract]. Arthritis Rheum 2009;60 Suppl:S416.
14. Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007;34:1888-93. (Pubitemid 350067651)
15. Schumacher HR Jr, Becker MA, Edwards NL, Palmer WE, MacDonald PA, Palo W, et al. Magnetic resonance imaging in the quantitative assessment of gouty tophi. Int J Clin Pract 2006;60:408-14.
16. Dalbeth N, Clark B, Gregory K, Gamble GD, Doyle A, McQueen FM. Computed tomography measurement of tophus volume: comparison with physical measurement. Arthritis Rheum 2007;57:461-5. (Pubitemid 46682534)
17. Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K, Reid G, et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis 2009;68:1609-12.